• share
• favorite_border

As scientists race to develop and test new treatments for COVID-19, Dana-Farber’s Wayne Marasco, MD, PhD, and his lab team are bringing one of the world’s most formidable resources to the effort: a “library” of 27 billion human antibodies against viruses, bacteria, and other bodily invaders.The collection, created by Marasco and his associates in 1997 using blood samples from more than 57 Dana-Farber staff, has already had an illustrious history in the quest to tame viral disease outbreaks.

• share
• favorite_border

New information from NCCN, ASCO, ASH, CDC, FDA, and others seeks to provide clear guidance on how to optimally manage cancer-related pain without exacerbating the ongoing opioid crisis—published jointly in the Journal of the National Comprehensive Cancer Network and JCO Oncology Practice.

• share
• favorite_border

Benjamin Brewer, PsyD, is a University of Colorado Cancer Center investigator and health psychologist at the UCHealth University of Colorado Hospital Bone Marrow Transplant Program. Here CU Cancer Center talks with Dr. Brewer about his patients’ new worries and about how our health system is adapting to meet the mental health needs of cancer patients during COVID-19.

• share
• favorite_border

New research from Roswell Park Comprehensive Cancer Center, published in the Journal of the National Cancer Institute, shows that following those guidelines can improve clinical outcomes for patients with high-risk breast cancer, or breast cancer that is likely to recur or spread.

• share
• favorite_border

Rutgers Cancer Institute of New Jersey, a National Cancer Institute-designated Comprehensive Cancer Center, is offering a clinical trial as a potential treatment for patients diagnosed with the coronavirus (COVID-19). The trial, which is not limited to cancer patients is exploring hydroxychloroquine and azithromycin.

• share
• favorite_border

Summaries of recent Fred Hutch research findings with links for additional background and media contacts.

• share
• favorite_border

Live, single-cell imaging shows that cells continuously integrate the influence of growth factors, not just during G1 phase of cell cycle, as previously thought.

• share
• favorite_border

Majority of patients responded in CAR T-cell trial for mantle cell lymphoma. Study showed 93% of patients responded with 67% achieving complete response.

• share
• favorite_border

A subset of patients with metastatic prostate cancer and specific markers of immune activity responded well to treatment with immune checkpoint inhibitors, according to results of a Phase II trial.

• share
• favorite_border